title: Immunotherapy for infectious diseases in haematological immunocompromise.
abstract: Opportunistic infections remain a major problem across a broad spectrum of immunocompromised haematological patient groups, with viruses, bacteria, fungi and protozoa all presenting significant challenges. Given the major difficulties in treating many of these infections with the currently available antimicrobial chemotherapeutic arsenal, and the rapid emergence of antimicrobial resistance amongst all of the microbial kingdoms, novel strategies that enable host control or elimination of infection are urgently required. Recently, major progress has been made in our understanding of host immunocompromise in the haematological patient. In addition, a wide range of novel immunomodulatory strategies for infectious diseases have been developed. Here we discuss the major and wide-ranging areas of progress that have been made for host-directed immunotherapies in the context of infectious diseases, with relevance to haematological immunocompromise.
authors.affiliation: Department of Virology, Kings College Hospital, London, UK.
authors.forename: Maria-Teresa
authors.initials: MT
authors.lastname: Cutino-Moguel
authors.affiliation: Department of Infectious Diseases, Imperial College Healthcare NHS Trust, London, UK.
authors.forename: Chris
authors.initials: C
authors.lastname: Eades
authors.affiliation: Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Centre, Houston, TX, USA.
authors.forename: Katayoun
authors.initials: K
authors.lastname: Rezvani
authors.affiliation: Fungal Pathogens Laboratory, National Heart and Lung Institute, Imperial College London, London, UK.
authors.forename: Darius
authors.identifier: 0000-0002-1014-7343
authors.initials: D
authors.lastname: Armstrong-James
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use; D006402:Hematologic Diseases / Q000150:complications / Q000276:immunology* / Q000628:therapy; D006801:Humans; D016867:Immunocompromised Host; D007136:Immunoglobulins / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D009894:Opportunistic Infections / Q000150:complications / Q000276:immunology / Q000628:therapy*; D019936:Probiotics / Q000627:therapeutic use; D014612:Vaccines
chemical_list: D003115:Colony-Stimulating Factors; D016207:Cytokines; D007136:Immunoglobulins; D014612:Vaccines
keywords: Infection; antibodies; cell therapy; cytokines; immunotherapy